Back

Impact of 18FDG-avidity and immunosuppression on idiopathic and genetic cardiomyopathies

2026-02-03 cardiovascular medicine Title + abstract only
View on medRxiv
Show abstract

BackgroundMyocardial 18fluorodeoxyglucose (18FDG)-avidity is frequently seen in patients with genetic cardiomyopathy (CMP), as well as a growing "idiopathic 18FDG-avidity" group of genotype-negative patients who do not clearly have cardiac sarcoidosis (CS). ObjectivesTo determine the prognostic implications of 18FDG-avidity in patients with and without genetic CMP, and the effects of immunosuppression in the latter. MethodsThis multicenter, retrospective study included all patients who were re...

Predicted journal destinations